Repligen Income Tax Expense vs Research Development Analysis

RGEN Stock

USD 151.94 2.78 1.80%

Repligen financial indicator trend analysis is much more than just breaking down Repligen prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repligen is a good investment. Please check the relationship between Repligen Income Tax Expense and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.

Income Tax Expense vs Research Development

Income Tax Expense vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repligen Income Tax Expense account and Research Development. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Repligen's Income Tax Expense and Research Development is 0.16. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of Repligen, assuming nothing else is changed. The correlation between historical values of Repligen's Income Tax Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Repligen are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Income Tax Expense i.e., Repligen's Income Tax Expense and Research Development go up and down completely randomly.

Correlation Coefficient

0.16

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Income Tax Expense

Research Development

Most indicators from Repligen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repligen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.At this time, Repligen's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Enterprise Value Over EBITDA is likely to grow to 82.01, while Tax Provision is likely to drop about 7.4 M.

	2021	2022	2023	2024 (projected)
Gross Profit	391.3M	455.7M	284.2M	538.9M
Total Revenue	670.5M	801.5M	638.8M	768.0M

Gross Profit Total Revenue

Repligen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Accounts Payable	Short Term Debt	Other Assets	Common Stock Total Equity	Short Term Investments
Total Assets		0.94	0.93	0.78	0.81	0.95	-0.38	0.93	0.96	0.97	0.11	0.97	0.97	0.61	0.82	0.96	0.95	0.91	0.97	0.94	0.99	0.86	0.49	0.36	0.78	0.12
Short Long Term Debt Total	0.94		0.79	0.57	0.89	0.95	-0.13	0.94	0.89	0.93	0.1	0.89	0.93	0.49	0.95	0.9	0.95	0.84	0.97	0.95	0.92	0.72	0.27	0.28	0.66	0.01
Other Current Liab	0.93	0.79		0.9	0.73	0.89	-0.43	0.84	0.86	0.93	0.13	0.88	0.95	0.73	0.64	0.95	0.86	0.9	0.89	0.87	0.92	0.97	0.69	0.24	0.81	0.23
Total Current Liabilities	0.78	0.57	0.9		0.48	0.72	-0.57	0.68	0.74	0.79	0.04	0.78	0.82	0.72	0.33	0.82	0.73	0.83	0.7	0.68	0.8	0.91	0.87	0.16	0.75	0.34
Total Stockholder Equity	0.81	0.89	0.73	0.48		0.85	0.01	0.83	0.73	0.82	0.11	0.72	0.85	0.33	0.86	0.81	0.91	0.77	0.87	0.88	0.77	0.71	0.23	0.27	0.5	-0.18
Property Plant And Equipment Net	0.95	0.95	0.89	0.72	0.85		-0.11	0.98	0.85	0.96	0.11	0.87	0.97	0.53	0.85	0.99	0.95	0.89	0.97	1.0	0.93	0.83	0.45	0.27	0.69	0.24
Net Debt	-0.38	-0.13	-0.43	-0.57	0.01	-0.11		-0.08	-0.56	-0.33	0.04	-0.54	-0.3	-0.59	0.02	-0.22	-0.25	-0.36	-0.24	-0.06	-0.46	-0.44	-0.48	-0.12	-0.58	0.18
Retained Earnings	0.93	0.94	0.84	0.68	0.83	0.98	-0.08		0.84	0.94	0.16	0.86	0.95	0.45	0.86	0.96	0.93	0.87	0.96	0.98	0.91	0.77	0.38	0.22	0.66	0.22
Cash	0.96	0.89	0.86	0.74	0.73	0.85	-0.56	0.84		0.94	0.13	1.0	0.92	0.66	0.79	0.86	0.9	0.86	0.94	0.83	0.98	0.81	0.43	0.23	0.84	-0.07
Non Current Assets Total	0.97	0.93	0.93	0.79	0.82	0.96	-0.33	0.94	0.94		0.2	0.96	0.99	0.64	0.84	0.97	0.95	0.91	0.99	0.94	0.98	0.88	0.48	0.14	0.82	0.08
Non Currrent Assets Other	0.11	0.1	0.13	0.04	0.11	0.11	0.04	0.16	0.13	0.2		0.13	0.15	0.01	0.2	0.14	0.11	0.2	0.17	0.11	0.14	0.1	-0.02	-0.33	0.18	-0.17
Cash And Short Term Investments	0.97	0.89	0.88	0.78	0.72	0.87	-0.54	0.86	1.0	0.96	0.13		0.94	0.68	0.78	0.89	0.91	0.88	0.94	0.85	0.99	0.82	0.47	0.25	0.84	0.01
Net Receivables	0.97	0.93	0.95	0.82	0.85	0.97	-0.3	0.95	0.92	0.99	0.15	0.94		0.65	0.81	0.98	0.96	0.93	0.98	0.96	0.97	0.91	0.55	0.2	0.79	0.13
Common Stock Shares Outstanding	0.61	0.49	0.73	0.72	0.33	0.53	-0.59	0.45	0.66	0.64	0.01	0.68	0.65		0.33	0.62	0.51	0.59	0.57	0.49	0.68	0.73	0.63	-0.05	0.89	0.16
Non Current Liabilities Total	0.82	0.95	0.64	0.33	0.86	0.85	0.02	0.86	0.79	0.84	0.2	0.78	0.81	0.33		0.78	0.84	0.68	0.91	0.87	0.8	0.55	-0.01	0.19	0.55	-0.15
Inventory	0.96	0.9	0.95	0.82	0.81	0.99	-0.22	0.96	0.86	0.97	0.14	0.89	0.98	0.62	0.78		0.93	0.92	0.96	0.97	0.94	0.9	0.58	0.22	0.75	0.29
Other Current Assets	0.95	0.95	0.86	0.73	0.91	0.95	-0.25	0.93	0.9	0.95	0.11	0.91	0.96	0.51	0.84	0.93		0.94	0.96	0.94	0.94	0.82	0.46	0.29	0.69	0.0
Other Stockholder Equity	0.91	0.84	0.9	0.83	0.77	0.89	-0.36	0.87	0.86	0.91	0.2	0.88	0.93	0.59	0.68	0.92	0.94		0.89	0.87	0.91	0.85	0.68	0.23	0.72	0.15
Total Liab	0.97	0.97	0.89	0.7	0.87	0.97	-0.24	0.96	0.94	0.99	0.17	0.94	0.98	0.57	0.91	0.96	0.96	0.89		0.96	0.97	0.83	0.38	0.22	0.76	0.04
Property Plant And Equipment Gross	0.94	0.95	0.87	0.68	0.88	1.0	-0.06	0.98	0.83	0.94	0.11	0.85	0.96	0.49	0.87	0.97	0.94	0.87	0.96		0.9	0.81	0.42	0.27	0.66	0.22
Total Current Assets	0.99	0.92	0.92	0.8	0.77	0.93	-0.46	0.91	0.98	0.98	0.14	0.99	0.97	0.68	0.8	0.94	0.94	0.91	0.97	0.9		0.87	0.51	0.24	0.84	0.07
Accounts Payable	0.86	0.72	0.97	0.91	0.71	0.83	-0.44	0.77	0.81	0.88	0.1	0.82	0.91	0.73	0.55	0.9	0.82	0.85	0.83	0.81	0.87		0.72	0.17	0.78	0.18
Short Term Debt	0.49	0.27	0.69	0.87	0.23	0.45	-0.48	0.38	0.43	0.48	-0.02	0.47	0.55	0.63	-0.01	0.58	0.46	0.68	0.38	0.42	0.51	0.72		0.11	0.5	0.47
Other Assets	0.36	0.28	0.24	0.16	0.27	0.27	-0.12	0.22	0.23	0.14	-0.33	0.25	0.2	-0.05	0.19	0.22	0.29	0.23	0.22	0.27	0.24	0.17	0.11		-0.01	0.2
Common Stock Total Equity	0.78	0.66	0.81	0.75	0.5	0.69	-0.58	0.66	0.84	0.82	0.18	0.84	0.79	0.89	0.55	0.75	0.69	0.72	0.76	0.66	0.84	0.78	0.5	-0.01		0.05
Short Term Investments	0.12	0.01	0.23	0.34	-0.18	0.24	0.18	0.22	-0.07	0.08	-0.17	0.01	0.13	0.16	-0.15	0.29	0.0	0.15	0.04	0.22	0.07	0.18	0.47	0.2	0.05

Click cells to compare fundamentals

Repligen Account Relationship Matchups

Repligen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4B	1.9B	2.4B	2.5B	2.8B	3.0B
Short Long Term Debt Total	263.3M	275.4M	366.1M	423.0M	711.8M	747.4M
Other Current Liab	28.3M	36.3M	70.5M	63.3M	46.4M	48.7M
Total Current Liabilities	48.3M	319.0M	375.3M	404.2M	158.2M	166.1M
Total Stockholder Equity	5.8M	65.8M	1.8B	397.3M	2.0B	2.1B
Property Plant And Equipment Net	74.2M	92.0M	226.5M	315.7M	323.0M	339.1M
Net Debt	(265.1M)	(441.9M)	(237.8M)	(100.5M)	(39.5M)	(41.5M)
Retained Earnings	5.8M	65.8M	194.1M	397.3M	438.8M	460.8M
Cash	528.4M	717.3M	603.8M	523.5M	751.3M	788.9M
Non Current Assets Total	758.3M	1.0B	1.4B	1.5B	1.7B	1.8B
Non Currrent Assets Other	238K	573K	615K	815K	1.3M	1.3M
Cash And Short Term Investments	528.4M	717.3M	603.8M	623.8M	751.3M	788.9M
Net Receivables	43.7M	71.4M	117.4M	116.2M	124.2M	130.4M
Common Stock Shares Outstanding	49.2M	53.9M	57.3M	57.5M	56.4M	29.9M
Liabilities And Stockholders Equity	346.2M	439.5M	2.4B	1.0B	2.8B	3.0B
Non Current Liabilities Total	292.0M	54.8M	233.0M	209.8M	695.0M	729.8M
Inventory	54.8M	95.0M	184.5M	238.3M	202.3M	212.4M
Other Current Assets	3.1M	18.7M	25.9M	19.8M	33.2M	34.9M
Other Stockholder Equity	14.5M	1.5B	1.6B	1.5B	1.6B	1.6B
Total Liab	340.3M	373.7M	608.3M	614.0M	853.2M	895.9M
Property Plant And Equipment Gross	74.2M	92.0M	297.2M	408.0M	451.7M	474.3M
Total Current Assets	641.8M	902.4M	931.7M	998.1M	1.1B	1.2B
Accumulated Other Comprehensive Income	(15.0M)	2.1M	(16.9M)	(34.4M)	(37.4M)	(35.6M)
Accounts Payable	11.4M	16.9M	36.2M	27.6M	19.6M	20.5M
Short Term Debt	3.6M	249.0M	263.6M	291.6M	75.1M	101.1M
Other Assets	3.2M	28.2M	2.5M	1.7M	1.5M	1.6M
Common Stock Total Equity	521K	548K	553K	556K	639.4K	389.2K
Common Stock	521K	548K	553K	556K	558K	398.5K
Property Plant Equipment	48.5M	66.9M	125.0M	190.7M	219.3M	230.2M
Other Liab	32.3M	28.4M	130.5M	78.4M	90.1M	94.6M
Current Deferred Revenue	5.0M	15.3M	14.8M	19.3M	10.3M	5.4M
Good Will	468.4M	618.3M	860.4M	855.5M	987.1M	1.0B
Intangible Assets	212.6M	287.1M	337.3M	353.7M	400.5M	420.5M
Net Tangible Assets	378.8M	623.7M	552.4M	701.5M	806.7M	847.1M
Retained Earnings Total Equity	5.8M	65.8M	194.1M	397.3M	456.9M	479.7M
Capital Surpluse	1.1B	1.5B	1.6B	1.5B	1.8B	1.9B

Pair Trading with Repligen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Repligen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Repligen will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Repligen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Repligen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Repligen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Repligen to buy it.

The correlation of Repligen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Repligen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Repligen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Repligen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:

How To Invest In Repligen

Details

Is Repligen Stock a good investment?

Details

What is Repligen's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.83)

Earnings Share

(0.03)

Revenue Per Share

11.452

Quarterly Revenue Growth

0.097

Return On Assets

0.002

The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Repligen Income Tax Expense vs Research Development Analysis

Income Tax Expense vs Research Development

Income Tax Expense vs Research Development Correlation Analysis

Correlation Coefficient

Income Tax Expense

Research Development

Repligen fundamental ratios Correlations

Repligen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Repligen fundamental ratios Accounts

Pair Trading with Repligen

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Inventory	+ 0.99	Property Plant And Equipment Net
Net Receivables	+ 0.99	Non Current Assets Total
Total Liab	+ 0.99	Non Current Assets Total

Common Stock Shares Outstanding	- 0.59	Net Debt
Common Stock Total Equity	- 0.58	Net Debt
Net Debt	- 0.57	Total Current Liabilities
Cash	- 0.56	Net Debt
Cash And Short Term Investments	- 0.54	Net Debt
Short Term Debt	- 0.48	Net Debt